Use of erlotinib throughout pregnancy: a case-report of a patient with metastatic lung adenocarcinoma

Vista sencilla de ítem
dc.contributor.authorRivas, Giovanna
dc.contributor.authorLlinás, Nestor
dc.contributor.authorBonilla, Carlos
dc.contributor.authorRubiano, Juan
dc.contributor.authorCuello, Javier
dc.contributor.authorArango, Natalia
dc.date.accessioned2020-09-14T21:44:27Z
dc.date.available2020-09-14T21:44:27Z
dc.date.issued2012
dc.description.abstractenglishThe use of erlotinib throughout pregnancy has not been previously reported. We present the case of a 40 year-old female patient with stage IV lung adenocarcinoma, mediastinal, bone and cerebral metastasis, a EGFR mutation and no smoking history, who had begun first line treatment with erlotinib 150 mg once daily. After two and a half months of treatment a fourteen-week pregnancy was documented, and after informing on fetal risks secondary to erlotinib use and maternal risks secondary to treatment withholding, she decided to continue with treatment under clinical surveillance by both the oncology and obstetrics clinics. At thirty-three weeks gestation a live born 1600 g female was born by caesarean section without evidence of congenital malformations. Imaging assessment after eight months of treatment showed complete bone and central nervous system response and partial lung and mediastinal response. The patient is currently undergoing the 11th month of treatment and is asymptomatic, the baby is 4 months old and is in good health.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1016/j.lungcan.2012.03.026
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.issn1872-8332
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlhttps://repositorio.unbosque.edu.co
dc.identifier.urihttps://hdl.handle.net/20.500.12495/4083
dc.language.isoeng
dc.publisherElsevierspa
dc.publisher.journalLung Cancerspa
dc.relation.ispartofseriesLung Cancer, 1872-8332, Vol. 77, No. 2, 2012 p. 469-472spa
dc.relation.urihttps://www.lungcancerjournal.info/article/S0169-5002(12)00172-9/fulltext
dc.rights.accessrightshttps://purl.org/coar/access_right/c_abf2
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.accessrightsAcceso abierto
dc.rights.creativecommons2012-08
dc.rights.localAcceso abiertospa
dc.subject.decsNeoplasias pulmonaresspa
dc.subject.decsNeoplasias del sistema respiratoriospa
dc.subject.decsEmbarazospa
dc.subject.keywordsLung cancerspa
dc.subject.keywordsTreatmentspa
dc.subject.keywordsMetastasisspa
dc.subject.keywordsNon-small cell lung carcinomaspa
dc.subject.keywordsLung adenocarcinomaspa
dc.subject.keywordsErlotinibspa
dc.subject.keywordsPregnancyspa
dc.subject.keywordsEGFR tyrosine kinase inhibitorspa
dc.titleUse of erlotinib throughout pregnancy: a case-report of a patient with metastatic lung adenocarcinomaspa
dc.title.translatedUse of erlotinib throughout pregnancy: a case-report of a patient with metastatic lung adenocarcinomaspa
dc.type.coarhttps://purl.org/coar/resource_type/c_6501
dc.type.driverinfo:eu-repo/semantics/article
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.type.localArtículo de revista

Archivos

Bloque original
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
Rivas_Giovanna_2012.pdf
Tamaño:
695.17 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos